Fujiwara K, Eguchi K
Department of Internal Medicine, National Shikoku Cancer Center Hospital.
Nihon Rinsho. 2000 May;58(5):1087-92.
Chemotherapy is currently a primary treatment modality for small-cell lung cancer (SCLC). Combination chemotherapy of anticancer agents improves survival and mortality rather than chemotherapy with single agent. On the other hand, the role of chemotherapy in advanced non-small cell lung cancer(NSCLC) is still controversial. Several meta-analysis demonstrated a small but significant survival benefit of cisplatin-based chemotherapy. In the limited stage SCLC and locally advanced NSCLC, a combination of chemotherapy and thoracic irradiation was found to be superior to chemotherapy alone by several randomized trials and meta-analysis. Concurrent administration of anticancer agents with thoracic irradiation may be optimal treatment. In the last few years, several new agents have demonstrated antitumor activity against lung cancer and randomized trials of these drugs are now under way.
化疗目前是小细胞肺癌（SCLC）的主要治疗方式。抗癌药物联合化疗可提高生存率和降低死亡率，而非单药化疗。另一方面，化疗在晚期非小细胞肺癌（NSCLC）中的作用仍存在争议。多项荟萃分析表明，基于顺铂的化疗有微小但显著的生存获益。在局限期小细胞肺癌和局部晚期非小细胞肺癌中，多项随机试验和荟萃分析发现，化疗与胸部放疗联合优于单纯化疗。抗癌药物与胸部放疗同时给药可能是最佳治疗方案。在过去几年中，几种新药已显示出对肺癌的抗肿瘤活性，目前这些药物的随机试验正在进行中。
